DJIA 17,689.86 0.00 0.00%
NASDAQ 5,128.28 0.00 0.00%
S&P 500 2,103.84 0.00 0.00%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Commit To Buy Regeneron Pharmaceuticals At $370, Earn 6.2% Using Options

5 Big Upcoming FDA Decisions Expected in July

This Could Be Johnson & Johnson’s Future

As competition heats up for Johnson & Johnson's current blockbuster drugs like Zytiga and Remicade, we have to look into the pipeline to see what the future could hold.

Why Praluent Could Be Blockbuster For Regeneron

Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug?

IBB, CELG, AMGN, REGN: Large Inflows Detected at ETF

What Is Beyond Vision-Loss Blockbuster For Regeneron?

Jim Cramer's Top Takeaways: Celgene, Gilead Sciences, Regeneron, Alarm.com, TransUnion

Regeneron/Bayer's Eylea Gets Label Expansion in Japan - Analyst Blog

Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the N

Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication
See More Articles...